SWOG-S1117

Trial

Clinical Trial Title

SWOG-S1117

Trial Status

Open to Enrollment

Start Date

February 22, 2013

Location

Trial Type

Cancer (Oncology)

Specific Condition

Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Description

A Randomized Phase II Study of Azactitdine in Combination with Lenadlidomide vs. Azactidine Alone vs. Azactitdine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Eligibility Criteria

  • Patients must have morphologically confirmed diagnosis of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)
  • Patients must not have received lenalidomide, azacitidine, vorinostat or decitabine as treatment previously

  • Patients must not have undergone prior allogeneic stem cell or bone marrow transplantation at any time. Patients that have undergone an autologous stem cell transplant are eligible.

     

IRB Number

IRB00009229

Notes

Sponsored by: SWOG Southwest Oncology Group

Principal Investigator Name

Jacqueline Vuky, MD

Contact Name

Legacy Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Last Updated: Wednesday, September 18, 2013 01:48:13 PM

We'd like to make your experience better.
x

Help us improve our site and be entered to win a $100 gift card.

Take the Survey